

Electronic supplementary material

Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study

Clinical and Experimental Nephrology

Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, Masaomi Nangaku, Takashi Wada,
Yasuyuki Okuda, Tomoko Sawanobori

Corresponding author:

Sadayoshi Ito, MD, PhD

Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine,
Tohoku University School of Medicine, 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi 980-8575,
Japan

E-mail: db554@med.tohoku.ac.jp

Online Resource 5 Proportion of patients with UACR reduction at the end of treatment

Category	Esaxerenone <i>n</i> = 56	95% CI
Patients with improvement in albuminuria ^a , <i>n</i> (%)	29 (51.8)	[38.0, 65.3]
Patients with transition to microalbuminuria ^b , <i>n</i> (%)	29 (51.8)	[38.0, 65.3]
Patients with ≥30% reduction in UACR, <i>n</i> (%)	42 (75.0)	[61.6, 85.6]
Patients with ≥50% reduction in UACR, <i>n</i> (%)	32 (57.1)	[43.2, 70.3]
Patients with ≥75% reduction in UACR, <i>n</i> (%)	9 (16.1)	[7.6, 28.3]

^aImprovement in albuminuria was defined as < 300 mg/g creatinine and 30% reduction from baseline on two consecutive measurements at the end of treatment

^bMicroalbuminuria was defined as two consecutive UACR values of <300 mg/g creatinine at the end of treatment.

CI confidence interval; *UACR* urinary albumin-to-creatinine ratio.